These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3030390)

  • 1. Immunoreactive prolyl hydroxylase in patients with primary and secondary myelofibrosis.
    Wang JC; Wong C; Kao WW
    Br J Haematol; 1987 Feb; 65(2):171-4. PubMed ID: 3030390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
    Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
    Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
    Arrago JP; Poirier O; Najean Y
    Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactive prolyl hydroxylase protein and galactosylhydroxylysyl glucosyltransferase activity in breast tissues and sera of patients with primary breast cancer.
    Bolarin DM
    Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):493-502. PubMed ID: 6304825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
    Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
    Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muramidase activity in leukemia and myeloproliferative disorders.
    Skarin AT; Matsuo Y; Moloney WC
    Oncology; 1973; 27(5):406-14. PubMed ID: 4515747
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
    Wang JC; Chen C; Dumlao T; Naik S; Chang T; Xiao YY; Sominsky I; Burton J
    Leuk Lymphoma; 2008 Dec; 49(12):2321-7. PubMed ID: 19052980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum procollagen III peptide in chronic myeloproliferative disorders.
    Hasselbalch H; Junker P; Lisse I; Bentsen KD
    Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
    Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
    Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
    Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
    Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone marrow fibrosis in malignant hemopathies and cancers. Histological study of 2 786 biopsies (author's transl)].
    Duhamel G; Stachowiak J
    Sem Hop; 1981 Jan 18-25; 57(3-4):111-6. PubMed ID: 6261348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
    Bolarin DM; Savolainen ER; Kivirikko KI
    Int J Cancer; 1982 Apr; 29(4):401-5. PubMed ID: 6282764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Coexistence of myelofibrosis and collagen diseases].
    Bistue R; Gallo de Sprazzato ME; Scognamillo CD; Porretta de Croceri L; Estevez MM; Guerra D
    Medicina (B Aires); 1990; 50(3):248-50. PubMed ID: 2130212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
    Buhr T; Georgii A; Choritz H
    Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro.
    Turpeenniemi-Hujanen T; Myllylä R
    Biochim Biophys Acta; 1984 Jul; 800(1):59-65. PubMed ID: 6331520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypocholesterolemia and other lipoprotein disorders in myelofibrosis].
    Kiss A; Telek B; Rák K
    Orv Hetil; 1994 Nov; 135(48):2643-6. PubMed ID: 7808738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
    Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
    Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.